𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Impact of disease severity on outcome of antiviral therapy in treatment-naïve patients with chronic hepatitis C

✍ Scribed by Johan Westin; Kristoffer Hellstrand; Åsa Alsiö; Magdalena Ydreborg; Carlo Ferrari; Avidan U. Neumann; Jean-Michel Pawlotsky; Solko W. Schalm; Stefan Zeuzem; Elke Verhey-Hart; Martin Lagging

Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
113 KB
Volume
45
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

✦ Synopsis

The results encourage a new HDV classification in which the Deltavirus genus consists of 8 major clades, 5 of them being present in Africa (i.e., clade 1, 5, 6, 7, and 8). 7 Interestingly, clade 5 isolates represent approximately 20% of HDV RNA-positive samples, which is stable for the time period in France. Collaborative studies that include a large number of HDV-infected patients will be necessary to evaluate whether HDV clades are associated with different response to pegylated interferon.

📜 SIMILAR VOLUMES

Impact of disease severity on outcome of
Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial
✍ Gregory T. Everson; John C. Hoefs; Leonard B. Seeff; Herbert L. Bonkovsky; Deepa 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 352 KB 👁 1 views

In patients with chronic hepatitis C, advanced fibrosis and cirrhosis are associated with lower rates of sustained virologic response (SVR) to interferon (IFN)-based therapy. In this study, we assessed virologic response to retreatment with peginterferon alfa-2a and ribavirin (RBV), as a function of

Treatment of insulin resistance with met
Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin
✍ Manuel Romero-Gómez; Moisés Diago; Raúl J. Andrade; José L. Calleja; Javier Salm 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 309 KB 👁 1 views

Insulin resistance affects sustained virological response (SVR) in chronic hepatitis C. To know whether adding metformin to standard antiviral treatment improves SVR, we conducted a prospective, multicentered, randomized, double-blinded, placebo-controlled trial in 19 Spanish hospitals, including 12

A phase III study of the safety and effi
A phase III study of the safety and efficacy of viramidine versus ribavirin in treatment-naïve patients with chronic hepatitis C: ViSER1 results
✍ Yves Benhamou; Nezam H. Afdhal; David R. Nelson; Mitchell L. Shiffman; Deanine G 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 452 KB 👁 2 views

Pegylated interferon (peg-IFN) and ribavirin (RBV) are effective in eradicating the hepatitis C virus in more than half of patients. However, anemia arising from RBV-induced hemolysis can prompt dose reductions and lower sustained virologic response (SVR) rates. In early clinical trials, Viramidine

Prevalence and impact of hepatitis B and
Prevalence and impact of hepatitis B and C virus co-infections in antiretroviral treatment naïve patients with HIV infection at a major treatment center in Ghana
✍ Kwamena William Coleman Sagoe; Afrakoma Adjoa Agyei; Francesca Ziga; Margaret La 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB 👁 2 views

## Abstract Data on the effects of the presence of hepatitis B virus (HBV) and hepatitis C virus (HCV) in patients co‐infected with these viruses and HIV in West Africa are conflicting and little information is available in Ghana. A cohort of 138 treatment naïve individuals infected with HIV was sc

Severity of liver disease predicts the d
Severity of liver disease predicts the development of glucose abnormalities in patients with chronic hepatitis B or C following achievement of sustained virological response to antiviral therapy
✍ Wassim Chehadeh; Widad Al-Nakib 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 134 KB 👁 2 views

## Abstract A higher prevalence of glucose abnormalities has been reported in patients with hepatitis C virus (HCV) infection compared to patients with hepatitis B virus (HBV) infection. However, previous studies considered some confounding factors and ignored others, which might influence the comp

Timing of hepatitis C antiviral therapy
Timing of hepatitis C antiviral therapy in patients with advanced liver disease: A decision analysis model
✍ Sammy Saab; Douglas R. Hunt; Michael A. Stone; Amy McClune; Myron J. Tong 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 454 KB

Antiviral therapy for the treatment of hepatitis C virus (HCV) infection is used before and after liver transplantation. The objective of this study was to determine the most cost-effective timing for pegylated interferon/ribavirin therapy in patients with advanced liver disease infected with genoty